Author(s):
Kirubakaran. N., Umashankar M. S., Bhuvaneshwari S.
Email(s):
umashans@srmist.edu.in
DOI:
10.52711/0974-360X.2023.00930
Address:
Kirubakaran. N.1*, Umashankar M. S.2, Bhuvaneshwari S.3
1,3Research Scholar, Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, Tamil Nadu 603203.
2Professor, Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, Tamil Nadu 603203.
*Corresponding Author
Published In:
Volume - 16,
Issue - 12,
Year - 2023
ABSTRACT:
Objective: The aim of the current research was to design and develop an analytical method for the estimation of Oxetacaine and its quality control determinations of different formulation by reverse phase high performance liquid chromatography (RP-HPLC). Method: In Method I the Agilent HPLC used for the Estimation purpose. C-18 column (250 X 4.6mm i.e., 1µ) as stationary phase and 0.05% formic acid buffer: Methanol in the ratio 30:70 % v/v as mobile phase, with a flow rate of 1.0ml/min. Diluents of Methanol: water 90:10 ratio used for the study with ambient Temp conditions. In Method II the Agilent HPLC used for the Estimation purpose .C8 Column ((250 X 4.6mm i.e., 5µ) as stationary phase and ammonium phosphate buffer pH 4.8: Acetonitrile in the ratio 25:75 % v/v as mobile phase, with a flow rate of 0.9ml/min. Diluents of Acetonitryl: water 50:50 ratios used for the study with ambient Temp conditions. Result: Method 1: Oxetacaine standard (86µg/ml concentration) peak was eluted at average of 5.629min at 3 runs with Asymmetry of 1.29813 and Peak area of 23237896 with the conditions of %RSD of max2. With qualifying of system suitability, accuracy and reproducibility. Some of Marketed suspension formulations were operated under the same instrument conditions and the results were compared with standard Oxetacaine to ensure the percentage purity of Marketed suspensions. Method 2: Oxetacaine standard (196µg/ml concentration) peak was eluted at average of 4.884 min at 3 runs with Asymmetryof1.17244 and Peak area of 360543170 with the conditions of %RSD of max 2. With qualifying of system suitability, accuracy and reproducibility. Some of Marketed suspension formulations were operated under the same instrument conditions and the results were compared with standard Oxetacaine to ensure the percentage purity of Marketed suspensions. Conclusion: The two new method of estimation of oxetacaine like using Method 1: C18 column, 0.05% formic acid buffer: Methanol in the ratio 30:70 % v/v as mobile phase @214nm and Method 2: C8 Column, ammonium phosphate buffer pH 4.8: Acetonitrile in the ratio 25:75 % v/v as mobile phase @214 achieved with simple, precise, accurate and sensitive. In addition the quality control estimating of some of random of F1, F2, F3, F4, F5, and F6 marketed oxetacaine suspensions were analysed using this Two Optimized methods. Out of 6 formulations, 2 formulations F3, F6 determined as substandard quality on the both the methods. Hence proving these two new methods optimal for the further monograph inclusions as well as quality control predictions of oxetacaine in API as well as Finished Pharmaceutical Formulations.
Cite this article:
Kirubakaran. N., Umashankar M. S., Bhuvaneshwari S.. Analytical Methods of Estimation of Oxetacaine and its quality determinations in different Pharmaceutical Formulations by Reverse Phase High Performance Liquid Chromatography (RP-HPLC). Research Journal of Pharmacy and Technology. 2023; 16(12):5748-3. doi: 10.52711/0974-360X.2023.00930
Cite(Electronic):
Kirubakaran. N., Umashankar M. S., Bhuvaneshwari S.. Analytical Methods of Estimation of Oxetacaine and its quality determinations in different Pharmaceutical Formulations by Reverse Phase High Performance Liquid Chromatography (RP-HPLC). Research Journal of Pharmacy and Technology. 2023; 16(12):5748-3. doi: 10.52711/0974-360X.2023.00930 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-12-31
REFERENCES:
1. Seifter J, Glassman JM, Hudyma GM. Oxethazaine and related congeners: a series of highly potent local anesthetics. Proc Soc Exp Biol Med. 1962; 109(3): 664–8. doi:10.3181/00379727-109-27300
2. Balmforth GV, Samuel RK. Controlled Trial of Oxethazaine as an Analgesic in Duodenal Ulcer. Br Med J. 1964; 1(5379): 355-6. Doi: 10.1136/bmj.1.5379.355.
3. Parakh RK, Patil NS. Anaesthetic antacids: a review of its pharmacological properties and therapeutic efficacy. Int J Res Med Sci. 2018; 6: 383-93. https://doi.org/10.18203/2320-6012.ijrms20180005.
4. Sethi PD. High Performance Liquid Chromatography, New Delhi, 1st Edition, 2001
5. Narenderan ST, Babu B, Meyyanthan SN and Gowramma B. A validated analytical method for the estimation of Oxetacaine from its pharmaceutical formulation by RP-HPLC. Int. J. Res. Dev. Pharm. L. Sci. 2017; 6(5): 2764-2768. Doi: 10.13040/IJRDPL.2278-0238.6 (5).2764-2768.
6. Miller JM. Chromatography Concepts and Contrasts. New Jersey, 2nd Edition, 2005.
7. Ahmed S, Rizwana I, Vani MA and Azeez Basha SA: Stability Indicating Method Development and Validation of Sucralfate and Oxetacaine in Bulk and Marketed Formulation by RP-HPLC. Int J Pharm Sci Res. 2015; 6(5): 2133-39. Doi: 10.13040/IJPSR.0975-8232.6 (5).2133-39.
8. Sujitha Parimala S. Method development and validation of sucralfate and oxetacaine in bulk and marketed formulation by RP-HPLC. International Journal of Innovative Pharmaceutical Research. 2013; 4(4): 349-356.
9. Elzanfaly ES, Amer EA, Galal SA, Zaazaa HE. Stability indicating methods for selective determination of Oxetacaine in the presence of its degradation products. Bulletin of Faculty of Pharmacy, Cairo University. 2018; 56(2): 199-205. https://doi.org/10.1016/j.bfopcu.2018.10.002
10. D Nagavalli, ASK Sankar, K Anandakumar, T Vetrichelvan, M Balaji. Estimation of Metaxalone in Bulk and in Tablet Dosage Form by RP-HPLC. Research J. Pharm. and Tech. 2010; 3(2): 409-411.
11. R.V Rele, J.M. Parab, V.V. Mhatre, C.B. Warkar. Simultaneous RP-HPLC Determination of Diclofenac Potassium and Famotidine in Pharmaceutical Preparations. Research J. Pharm. and Tech. 2011; 4(4): 638-641.
12. Mounika P Siridevi, Hemant T Kumar, Srinivasa Y Rao, Vara Prasad K Rao. RP-HPLC Method for Quantification of Empagliflozin in Pharmaceutical Formulation. Asian J. Pharm. Tech. 2019; 9(3): 208-211. DOI: 10.5958/2231-5713.2019.00035.7
13. Kavitha J, Bonda Vismitha, Kokilambigai KS, Seetharaman R, Lakshmi KS. Validated HPTLC Method for the Estimation of Oxetacaine in Pharmaceutical Formulations. Research Journal of Pharmacy and Technology. 2021; 14(11): 5668-2. doi: 10.52711/0974-360X.2021.00985
14. Indian pharmacopoeia 2018; Government of India, Ministry of Health. Pharmacopoeia of India.
15. Watson DG. Pharmaceutical analysis. 2nd Edition, 2005.
16. H. S. Jumde, S. D. Mankar. Review on development of Analytical Method and Validation by Reverse Phase – High Performance Liquid Chromatography. Asian Journal of Pharmacy and Technology. 2022; 12(2): 179-2. DOI: 10.52711/2231-5713.2022.00030
17. Remi. S. L, Joyamma Varkey, A. Jayakumaran Nair, Vishnu. S. Sanjeev. Application of an Eco-friendly, Cost-effective Hydrotropic solution as mobile phase for the estimation and validation of Ornidazole in bulk and Pharmaceutical Formulation by RP-HPLC. Asian J. Res. Pharm. Sci. 2021; 11(1): 15-21. DOI: 10.5958/2231-5659.2021.00003.5
18. T. Gopi Raju, M. Gayatri Ramya, A. Rajesh, S. Kathirvel, Sanjay Kumar Gupta. ICH Guideline Practice- a Validated Stability- Indicating HPLC Method for the Determination of Efavirenz in Dosage Form. Res. J. Pharm. Dosage Form. and Tech. 2014; 6(1): 7-14.
19. Santanu Ghosh, BB Barik. Quantization of Aceclofenac in Pharmaceutical Formulations by RP-HPLC. Research J. Pharma. Dosage Forms and Tech. 2010; 2(1): 52-55.
20. Priyanka. R. Varade, Mahavir G. Narwade, Varsha N. Tambe. Method Development and Validation of Irbesartan by RP-HPLC Method. Research J. Science and Tech. 2020; 12(2): 131-135. DOI: 10.5958/2349-2988.2020.00016.9
21. Akash Shelke, Someshwar Mankar, Mahesh Kolhe. Development and Validation of RP-HPLC Method for estimation of Secnidazole in API and Pharmaceutical Dosage Form. Research Journal of Science and Technology. 2021; 13(2): 100-4. DOI: 10.52711/2349-2988.2021.00015